

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	<b>RESAPP HEALTH LIMITED</b>
<b>ABN</b>	<b>51 094 468 318</b>

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Dr Michael Stein
<b>Date of last notice</b>	6 April 2020

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Not applicable
<b>Date of change</b>	2 December 2020
<b>No. of securities held prior to change</b>	Nil
<b>Class</b>	Director Incentive Options (exercisable at \$0.16; expiring 2 December 2023)
<b>Number acquired</b>	500,000 Director Incentive Options
<b>Number disposed</b>	Nil

---

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	Director Incentive Options issued as an incentive for Dr Stein to provide ongoing dedicated service to the Company as set out in the Company's Notice of Annual General Meeting lodged with ASX on 26 October 2020
<b>No. of securities held after change</b>	500,000 Director Incentive Options
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Director Incentive Options issued as approved by Shareholders at the Annual General Meeting held on 26 November 2020

## Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	Engagement as non-executive director, appointed 6 April 2020 (as set out in ASX Appendix 3X lodged 6 April 2020)
<b>Nature of interest</b>	Options issued under Company's ESOP as approved by Shareholders at the Annual General Meeting held on 26 November 2020
<b>Name of registered holder (if issued securities)</b>	Michael Stein
<b>Date of change</b>	2 December 2020
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	500,000 ESOP Options (exercisable at \$0.16; expiring 2 December 2023)
<b>Interest acquired</b>	Not applicable
<b>Interest disposed</b>	Options issued (post Shareholder Approval)
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	Options issued as an incentive as set out in the Company's Notice of Annual General Meeting
<b>Interest after change</b>	Nil interest in contracts – Options have been issued

+ See chapter 19 for defined terms.

**Part 3 – +Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	Not applicable
<b>If prior written clearance was provided, on what date was this provided?</b>	Not applicable

---

+ See chapter 19 for defined terms.